{
    "clinical_study": {
        "@rank": "68671", 
        "acronym": "MetRPL", 
        "arm_group": {
            "arm_group_label": "Metformin", 
            "arm_group_type": "Experimental", 
            "description": "The patients with PCO and hyper insulinemia will be subdivided into  two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive"
        }, 
        "brief_summary": {
            "textblock": "The prevalence of insulin resistance is increased in women with recurrent miscarriage\n      compared with matched fertile controls,Insulin resistance (IR) in this syndrome is not only\n      implicated toward early pregnancy loss (EPL) but also pathognomic for various obstetrical\n      complications during pregnancy.An elevated free androgen index appears to be a prognostic\n      factor for a subsequent miscarriage in women with recurrent miscarriage.\n\n      There is insufficient evidence to evaluate the effect of metformin supplementation in\n      pregnancy to prevent a miscarriage in women with recurrent miscarriage."
        }, 
        "brief_title": "Effectiveness of Metformin in Recurrent Miscarriage in a Woman With Hyperinsulinaemia", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Abortion, Habitual", 
        "condition_browse": {
            "mesh_term": [
                "Abortion, Spontaneous", 
                "Abortion, Habitual", 
                "Hyperinsulinism"
            ]
        }, 
        "detailed_description": {
            "textblock": "The patients with PCO and hyper insulinemia will be subdivided into  two groups, one group\n      will continue metformin 500 mg three times per day from the start of induction of ovulation\n      till the end of pregnancy, the other group will stop the drug once pregnancy test become\n      positive. Pregnancy follow up including the early and second trimester pregnancy loss,\n      Secondary outcomes like gestational diabetes, pregnancy-induced hypertension and\n      intrauterine growth restriction were also analyzed at the end of the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  women who are diagnosed to have PCOS and/or haven hyper insulinaemia and have a\n             previous history of recurrent miscarriages.\n\n        Exclusion Criteria:\n\n          -  Any patients with PCOS or hyper insulinaemia previously treated by any forms of\n             insulin sensitizers.\n\n        Age above forty years old .\n\n          -  Antiphospholipid syndrome (lupus anticoagulant and/or anticardiolipin antibodies [IgG\n             or IgM]); other recognised thrombophilic conditions (testing according to usual\n             clinic practice).\n\n          -  Intrauterine abnormalities (as assessed by ultrasound, hysterosonography,\n             hysterosalpingogram, or hysteroscopy).\n\n          -  Fibroids distorting uterine cavity .\n\n          -  Abnormal parental karyotype .\n\n          -  Other identifiable causes of recurrent miscarriages (tests initiated only if\n             clinically indicated) e.g., diabetes, thyroid disease and systemic lupus\n             erythematosus (SLE)."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "396", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718340", 
            "org_study_id": "MetRPL"
        }, 
        "intervention": {
            "arm_group_label": "Metformin", 
            "description": "metformin tablet 500mg three time per day", 
            "intervention_name": "Metformin", 
            "intervention_type": "Drug", 
            "other_name": [
                "glucophage", 
                "cidophage", 
                "amophage"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "PCOS", 
            "Hyper insulinaemia", 
            "metformin", 
            "recurrent abortion"
        ], 
        "lastchanged_date": "May 25, 2014", 
        "location": {
            "contact": {
                "email": "hkamelhkamel@yahoo.com", 
                "last_name": "Hassan S Kamel, M D"
            }, 
            "facility": {
                "address": {
                    "city": "Assiut", 
                    "country": "Egypt"
                }, 
                "name": "Women's Health Hospital"
            }, 
            "investigator": {
                "last_name": "Alaa mM Ismail, M D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Egypt"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 4 Study of Effectiveness of Metformin in Patients With Unexplained Recurrent Miscarriages", 
        "overall_contact": {
            "email": "dr.alaa_ismail@yahoo.com", 
            "last_name": "Alaa M Ismail, M D", 
            "phone": "+201000459514"
        }, 
        "overall_contact_backup": {
            "email": "hkamehkamel@yahoo.com", 
            "last_name": "Hassan S Kamel, M D", 
            "phone": "+"
        }, 
        "overall_official": {
            "affiliation": "Faculty of medicine,Assiut university,Egypt", 
            "last_name": "Alaa M Ismail, M D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Egypt: Institutional Review Board", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The patients with PCO and hyper insulinemia will be subdivided into  two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy,", 
            "measure": "The primary outcome is to evaluate the clinical pregnancy rate and the effectiveness of Metformin in the reduction of EPL in women with PCOS", 
            "safety_issue": "Yes", 
            "time_frame": "2 ys"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718340"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Woman's Health University Hospital, Egypt", 
            "investigator_full_name": "alaa eldeen mahmoud ismail", 
            "investigator_title": "M D", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "The patients with PCO and hyper insulinemia will be subdivided into  two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive. Pregnancy follow up including the early and second trimester pregnancy loss, Secondary outcomes like gestational diabetes, pregnancy-induced hypertension and intrauterine growth restriction were also analyzed at the end of the study.", 
            "measure": "Secondary outcomes like gestational diabetes, pregnancy-induced hypertension and intrauterine growth restriction were also analyzed at the end of the study and any fetal malformation", 
            "safety_issue": "Yes", 
            "time_frame": "2 ys"
        }, 
        "source": "Woman's Health University Hospital, Egypt", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Woman's Health University Hospital, Egypt", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}